Search results
Results from the Tech24 Deals Content Network
However, Viatris posted positive adjusted earnings per share of $0.69, up 3% year over year and topping the average analysts' estimate of $0.68. What investors liked the most about Viatris' Q2 update
When it made its debut last November, Viatris (VTRS) was touted as a value-unlocking divestiture. The pharmaceutical company, formed when Pfizer (PFE) merged its Upjohn unit with Mylan NV, started ...
In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, [21] and one of the 25 best companies offering career development in Ireland. [22] In May 2023, USA Today included Viatris in its list of 400 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. [23]
Viatris also reaffirmed its full-revenue revenue forecast to the range of $15.5 billion to $16 billion, compared to analysts' estimates of $15.60 billion. ... Japan's share benchmark soars nearly ...
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer 's off-patent medicine division, to form Viatris. [ 1] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK [ 2] and a "Global Center" in Canonsburg ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
(Reuters) - Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday, banking on strong demand for its branded drugs such as Yupelri for lung disease and Breyna for asthma.
Heather Bresch ( née Manchin; born June 27, 1969 [ 2]) is an American business executive. In 2012, she was named as the chief executive officer (CEO) of Netherlands-based pharmaceutical company Mylan, becoming the first woman to run a Fortune 500 pharmaceutical company. [ 3] Bresch retired in 2020, upon the closing of Mylan’s combination ...